Triple-negative breast cancer (TNBC) accounts for 10 to 20% of newly diagnosed invasive breast cancers and is defined by the absence of immunostaining for estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) [1]. This evidence concerns the gene PGR and triple-negative breast carcinoma.